Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423604 · ClinicalTrials.gov registry record · Phase 2
Study of Ruxolitinib in Pancreatic Cancer Patients
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT01423604: Completed Phase 2 study, sponsored by Incyte Corporation.
NCT01423604 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01423604, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
Primary Outcome
Overall survival was measured as the length of time (in days) between the randomization date and the date of death.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT01423604 record still lists
NCT01423604 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01423604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01423604 about?
NCT01423604 is a clinical study titled "Study of Ruxolitinib in Pancreatic Cancer Patients". The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
What is the current status of trial NCT01423604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2011-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01423604?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01423604?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01423604's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia